Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23385510 | 0.94 | LMNA (0.39) | ALDH1A1LMNASLC6A2SLC6A4SLC6A3 | |
| SCHEMBL17537235 | 0.83 | SLC6A2 (0.48) | ALDH1A1LMNASLC6A2SLC6A4CYP2D6 | |
| SCHEMBL19704415 | 0.76 | SLC6A2 (0.38) | ALDH1A1LMNASLC6A2SLC6A4SLC6A3 | |
| SCHEMBL30130613 | 0.76 | SLC6A2 (0.52) | ALDH1A1LMNASLC6A2SLC6A4SLC6A3 | |
| SCHEMBL17537087 | 0.76 | SLC6A2 (0.52) | ALDH1A1LMNASLC6A2SLC6A4SLC6A3 | |
| SCHEMBL3628082 | 0.75 | IRAK4 (0.44) | ALDH1A1LMNASLC6A2GAA | |
| SCHEMBL5432827 | 0.75 | G6PD (0.55) | ALDH1A1LMNASLC6A2RECQLPOLB | |
| SCHEMBL6183162 | 0.75 | GABRA1 (0.43) | LMNASLC6A2 | |
| SCHEMBL5283531 | 0.75 | NPC1 (0.45) | — | |
| SCHEMBL1887459 | 0.73 | ALDH1A1 (0.43) | ALDH1A1LMNASLC6A2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117105890-A | Amide derivative, preparation method thereof and application thereof in medicine | 成都百裕制药股份有限公司 | 2023-11-24 | — | — | CN | disclosed |
| US-20220411392-A1 | Amide Derivative And Preparation Method Therefore And Use Thereof In Medicine | CHENGDU BAIYU PHARMACEUTICAL CO., LTD. (CN) | 2022-12-29 | — | — | US | disclosed |
| WO-2021093820-A1 | AMIDE DERIVATIVE AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF IN MEDICINE | 成都百裕制药股份有限公司 | 2021-05-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220411392-A1 | Amide Derivative And Preparation Method Therefore And Use Thereof In Medicine | NLRP3, NLRP1, PYCARD | ALDH1A1 2160/4885LMNA 1520/4885SLC6A2 1570/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.